VALENCIA, Calif., August 18, 2026
AVITA Medical, Inc. announced positive results from the multicenter, randomized controlled PermeaDerm-I clinical study, demonstrating that its biosynthetic wound matrix PermeaDerm® provided comparable clinical outcomes to cadaveric allograft while delivering a 70% economic advantage based on product cost per percentage of total body surface area treated. The study achieved its primary endpoint with statistical significance (p<0.001), reporting an average treatment cost of $148.70 per 1% TBSA treated with PermeaDerm compared with $497.10 for allograft. The findings also showed a 95.7% reduction in preparation time, supported by PermeaDerm’s off-the-shelf availability and elimination of several tissue-bank requirements, including thawing, meshing and tissue-tracking logistics. The results position PermeaDerm as a potential economically advantaged option for temporary wound coverage between surgical excision and definitive skin grafting, particularly in acute wound and burn care settings.
PermeaDerm Delivers 70% Economic Advantage
The strongest finding from the PermeaDerm-I study was the substantial difference in treatment economics between PermeaDerm and cadaveric allograft. PermeaDerm demonstrated a mean treatment cost of $148.70 for every 1% TBSA treated, compared with $497.10 for allograft, producing a savings of approximately $348 per 1% TBSA. The study enrolled 40 patients across 11 U.S. burn centers, with participants receiving either PermeaDerm or cadaveric allograft following wound excision and before definitive split-thickness skin grafting. The economic advantage was accompanied by a major reduction in product preparation requirements. According to AVITA Medical, PermeaDerm reduced preparation time by 95.7%, primarily by eliminating tissue tracking, thawing and meshing procedures associated with allograft use. The product’s off-the-shelf format may therefore offer hospitals a more streamlined approach to temporary wound coverage while reducing operational requirements associated with tissue-bank products..
Clinical Outcomes Comparable to Allograft
The study also demonstrated that the economic benefits of PermeaDerm were accompanied by comparable clinical outcomes. Approximately 94% of PermeaDerm-treated patients achieved at least 95% graft take one week after autografting, a result reported as comparable with the allograft group. At eight weeks, all patients in both treatment groups achieved at least 95% wound healing, while no adverse events were attributed to PermeaDerm during the study. The findings are particularly relevant to temporary wound coverage, which provides protection and stabilization after excision while the wound bed becomes suitable for definitive closure. PermeaDerm is a transparent bilayer biosynthetic wound matrix, allowing clinicians to visualize the wound bed without removing the product. This feature, combined with its off-the-shelf availability, is intended to simplify workflow while maintaining wound protection during the temporization period. Investigator and patient satisfaction at final follow-up was also reported positively, with all responding participants indicating they were satisfied or very satisfied.
Advertisement
AVITA Medical Strengthens Acute Wound Care Portfolio
The positive PermeaDerm-I findings strengthen AVITA Medical’s acute wound care portfolio, which includes PermeaDerm alongside RECELL® and Cohealyx®. RECELL is an FDA-approved technology that uses a patient’s own skin to create Spray-On Skin™ for certain burn and trauma wounds, while PermeaDerm is designed for temporary wound coverage before definitive reconstruction. The company is positioning the new study data around two practical advantages: clinical comparability and reduced treatment economics. By eliminating several preparation and tissue-bank logistics, PermeaDerm could offer burn centers a simpler workflow for managing acute wounds requiring temporary coverage. The company also plans to use the findings to support broader awareness of the technology among clinicians and healthcare stakeholders. The PermeaDerm-I study was conducted as a post-market clinical trial, and its results provide additional evidence on the product’s economic and clinical performance in a multicenter U.S. burn-care setting. Together, the findings highlight the potential role of biosynthetic wound matrices in modern acute wound management and support AVITA Medical’s strategy of developing technologies aimed at improving wound-care efficiency and patient recovery.
Source: AVITA Medical, Inc.press relese
